BBS-Bioactive Bone Substitutes announces Dr Ilkka Kangasniemi to its Board of Directors

– FINLAND, Oulu –  BBS – Bioactive Bone Substitutes, an innovator in orthobiologics, today announced that the acclaimed Dr. Ilkka Kangasniemi has accepted an offer to join the company’s Board of Directors.

Pekka Jalovaara, CEO of BBS, commented “We are very pleased to announce that Dr. Kangasniemi has accepted our offer to join BBS’ Board of Directors. As Dr. Kangasniemi personally has participated in the development and commercialization of a number of products within biomaterials and bone implants, his expertise will be an important contribution to a successful shift from a pure research and development focused company to a profitable sales organization.”

About Dr. Ilkka Kangasniemi

Dr. Kangasniemi is a distinguished expert on biomaterials and bone implants and his competence will be of great value in the continued development of both the company and its product family Artebone, a bone graft substitute with natural growth factors extracted from reindeer bone.

Dr. Kangasniemi has during his long and withstanding career founded and successfully advanced a number of companies within the biomaterials field, as well as mentored and participated in a number of research projects. Since 2009, Dr. Kangasniemi serves as a docent of biomaterial science at the University of Turku, Finland, where he is responsible for the development of novel biomaterials as well as participated in the successful commercialization of them. In total, Dr. Kangasniemi has authored over 30 publications, submitted several patent applications, founded four biomaterial companies and successfully brought several products to market.

“Thanks to my combined business and research experience, I believe that I have developed a strong understanding of how and where technologies can be applied in clinical conditions as well as the process from early development to the commercialization of a technology, where BBS is now. This knowledge, I believe, will be of great aid as BBS now approaches the market with Artebone and I look forward to join as a board member of this promising company,” said Dr. Kangasniemi.

About BBS – Bioactive Bone Substitutes

BBS-Bioactive Bone Substitutes Plc is a leading orthobiologic biotech company with origins in Finland. The company’s technology, Artebone, is a next-generation bone substitute that targets treatment of bone defects and healing problems in extremities such as hands and ankles, scapula and pelvis. Its superior properties stem from the natural growth factors extracted from reindeer bone combined with scaffold-providing TCP granules and has the potential of transforming orthopedic surgery. The first product, Artebone Paste, is ready and the application process for the CE-marking enabling commercialization is in progress. BBS’ Certified Adviser at Nasdaq First North Sweden and Finland is Stockholm Certified Advisers AB.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>